Semax vs. Dihexa: Similar Pitch, Very Different Evidence Base

Semax and Dihexa get grouped together constantly in nootropic peptide discussions — both are small peptides derived from a natural hormone system, both are pitched as powerful cognitive enhancers, and both show up on the same vendor sites and forum threads. The similarity mostly ends there. One has real human clinical data behind it. The other's core scientific claim comes from a paper that has since been formally retracted for fabricated data. This isn't a close call once you look at the actual literature. What Semax Is Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from a fragment of adrenocorticotropic hormone (ACTH), developed by researchers at the Russian Academy of Sciences' Institute of Molecular Genetics. Despite its origin from ACTH — the hormone that stimulates cortisol production — Semax has no meaningful hormonal activity of its own; the fragment was found to retain cognitive and neuroprotective effects while losing the parent hormone's endocrine function. According to PubMed, Semax's mechanism has been directly studied at the molecular level: intranasal application in rats produced a measurable increase in brain-derived neurotrophic factor (BDNF) protein and its receptor (TrkB) in the hippocampus, alongside improved performance on a learning task ([Dolotov et al., Brain Research, 2006, PMID: 16996037](https://doi.org/10.1016/j.brainres.2006.07.108)). A companion study from the same research group found specific, saturable binding sites for Semax in the rat basal forebrain, with intranasal application producing a rapid, region-specific increase in BDNF levels — evidence of a genuine, targeted receptor interaction rather than a diffuse, nonspecific effect ([Dolotov et al., Journal of Neurochemistry, 2006, PMID: 16635254](https://doi.org/10.1111/j.1471-4159.2006.03658.x)). Critically, Semax also has real human clinical trial data behind it. According to PubMed, a clinical trial of 110 patients following ischemic stroke found that Semax administration increased plasma BDNF levels, which remained elevated throughout the study period, and was associated with accelerated functional recovery and improved motor performance scores compared to patients not receiving it ([Gusev et al., Zhurnal Nevrologii i Psikhiatrii, 2018, PMID: 29798983](https://doi.org/10.17116/jnevro20181183261-68)). Semax has been used in Russian clinical practice for stroke and cognitive impairment for years, based on this kind of trial data — it isn't just a preclinical curiosity. What Dihexa Is Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a synthetic compound derived from angiotensin IV, developed at Washington State University by researchers Joseph Harding and John Wright, with the specific goal of creating an orally bioavailable, blood-brain-barrier-penetrant molecule following decades of earlier angiotensin IV cognitive research. The proposed mechanism was genuinely novel: rather than acting on a classic neurotransmitter receptor, Dihexa was reported to potentiate hepatocyte growth factor (HGF) signaling through the c-Met receptor, driving synaptogenesis (new synapse formation) at a potency described as dramatically exceeding BDNF's own effects. This is where the story takes a serious turn. The foundational paper establishing this exact mechanism — the one demonstrating Dihexa's binding to HGF and its dependence on c-Met signaling for its cognitive effects — has been formally retracted. According to PubMed's own indexing, the paper is explicitly tagged as a "Retracted Publication" ([Benoist et al., Journal of Pharmacology and Experimental Therapeutics, 2014, PMID: 25187433](https://doi.org/10.1124/jpet.114.218735)). A Washington State University investigation found that specific figures and underlying data in the paper had been falsified and/or fabricated, and identified two of the paper's authors — Leen Kawas and Joseph Harding — as solely responsible. This isn't an isolated incident specific to one paper. Kawas, who was a PhD student under Harding at the time and later became CEO of Athira Pharma (a company built specifically to commercialize Dihexa-related compounds), was found by a separate WSU investigation to have altered images across her doctoral dissertation and at least four co-authored published papers between 2011 and 2014. She resigned from Athira Pharma in 2021 following these findings, and in January 2025, Athira Pharma paid approximately $4 million to settle federal False Claims Act allegations related to failing to report the misconduct. A second key mechanistic paper on the same compound has also been retracted, with a third carrying a formal Expression of Concern. Similarities Between the Two Setting the integrity issue aside for a moment, the two compounds do share a real conceptual similarity: both are small peptides repurposed from a native hormone system (ACTH for Semax, angiotensin IV for Dihexa) that were found to retain a cognitive or neurotrophic effect while losing most of the parent hormone's original endocrine function. Both are also proposed to work through neurotrophic/growth-factor signaling pathways rather than classic neurotransmitter receptor binding — Semax through BDNF/TrkB, Dihexa through the (now scientifically compromised) HGF/c-Met claim. Both are marketed heavily in nootropic and cognitive-enhancement communities, often in the same breath, which is precisely why a direct comparison matters. The Real Differences The differences are substantial, and they aren't close: Semax has multiple non-retracted, independently reproducible mechanistic studies and actual human clinical trial data — real patients, real outcome measures, real published results in the peer-reviewed literature, including decades of documented clinical use in Russia. Dihexa has zero human studies of any kind, and its foundational mechanistic claim — the entire basis for how it's supposed to work — comes from a paper that has been withdrawn from the scientific record due to confirmed data fabrication by the researchers who created and stood to financially benefit from it. There's also a legitimate independent safety question specific to Dihexa worth knowing regardless of the retraction: the HGF/c-Met pathway it's proposed to activate is a well-established, validated driver of cancer cell growth and metastasis in oncology research — a real, mechanistic reason for caution around chronically activating that specific pathway, separate from the fabrication issue entirely. Which One Is Actually Better This isn't a close comparison once you look at what's actually in the literature rather than what's claimed in marketing copy. Semax has real, non-retracted mechanistic research and genuine human clinical trial data behind it — it's a legitimate, if foreign and not FDA-approved, clinical compound with a real evidence trail. Dihexa's core scientific claim has been formally withdrawn from the peer-reviewed record for fabricated data, it has never been tested in a single human being, and the research program that produced it carries documented, financially consequential misconduct findings. It's worth being fair to Semax's actual limitations too: it isn't FDA-approved in the United States, its clinical trial base is entirely Russian-language and hasn't been replicated in large Western trials, and "used in Russian clinical practice" is a different standard of evidence than an FDA-approved drug. But that's a meaningfully different category of limitation than "the foundational paper was retracted for fabricated data" — one is a gap in regulatory approval and independent replication; the other is a confirmed integrity failure in the core evidence itself. The Bottom Line Semax and Dihexa get marketed as comparable nootropic peptides, but the evidence behind them isn't remotely comparable. Semax has real mechanistic studies that haven't been retracted and actual human clinical trial data showing measurable outcomes. Dihexa's entire mechanistic rationale rests on research that has been formally withdrawn from the scientific literature due to confirmed data fabrication, on top of having no human testing at all. If you're evaluating these based on the actual state of the published science rather than vendor marketing copy, this isn't a toss-up.